Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2017, Article ID 6139634, 3 pages
Case Report

Clinical Application of Liquid Biopsy in Targeted Therapy of Metastatic Colorectal Cancer

1Gastroenterology, Department of Medicine, Goethe University Frankfurt, Frankfurt, Germany
2IMBL Medical Clinic, Universitätsklinikum Knappschaftskrankenhaus Bochum, Bochum, Germany
3Department of Medicine, Hematology, and Oncology, Ruhr-University of Bochum, Bochum, Germany

Correspondence should be addressed to Alexander Baraniskin; ed.bur@niksinarab.rednaxela

Received 15 November 2016; Accepted 25 December 2016; Published 23 January 2017

Academic Editor: Jose I. Mayordomo

Copyright © 2017 Jörg Trojan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. S. Jones, D. Edelstein, K. Wichner et al., “Performance of standardized BEAMing platform for detecting RAS mutations in the blood of metastatic colorectal cancer (mCRC) patients,” Journal of Clinical Oncology, vol. 34, supplement, abstract 11538, 2016, Proceedings of the 2016 ASCO Annual Meeting. View at Google Scholar
  2. W. Schmiegel, R. Scott, S. Dooley et al., “Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing,” Molecular Oncology, 2016. View at Publisher · View at Google Scholar
  3. G. Siravegna, B. Mussolin, M. Buscarino et al., “Erratum: clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients,” Nature Medicine, vol. 21, no. 7, article 827, 2015. View at Publisher · View at Google Scholar
  4. M. P. Morelli, M. J. Overman, A. Dasari et al., “Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment,” Annals of Oncology, vol. 26, no. 4, pp. 731–736, 2015. View at Publisher · View at Google Scholar
  5. B. O. Van Emburgh, S. Arena, G. Siravegna et al., “Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer,” Nature Communications, vol. 7, Article ID 13665, 2016. View at Publisher · View at Google Scholar
  6. R. A. Toledo, A. Cubillo, E. Vega et al., “Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab,” Oncotarget, 2016. View at Publisher · View at Google Scholar
  7. A. S. Ekinci, U. Demirci, B. C. Oksuzoglu et al., “KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma,” Journal of BUON, vol. 20, no. 1, pp. 128–135, 2015. View at Google Scholar · View at Scopus
  8. K. H. Lee, J. S. Kim, C. S. Lee, and J. Y. Kim, “KRAS discordance between primary and recurrent tumors after radical resection of colorectal cancers,” Journal of Surgical Oncology, vol. 111, no. 8, pp. 1059–1064, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Nemecek, J. Berkovcova, L. Radova et al., “Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy,” OncoTargets and Therapy, vol. 9, pp. 4695–4703, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Fedyanin, A. Stroganova, A. Senderovich et al., “Factors associated with disconcordance of KRAS, NRAS, BRAF, PIK3CA mutation status in the primary tumor and metastases in patients (pts) with colorectal cancer (CRC),” Annals of Oncology, vol. 27, supplement 6, pp. 149–206, 2016. View at Publisher · View at Google Scholar
  11. D. Santini, B. Vincenzi, R. Addeo et al., “Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?” Annals of Oncology, vol. 23, no. 9, pp. 2313–2318, 2012. View at Publisher · View at Google Scholar · View at Scopus